Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial.
Koole SN, Schouten PC, Hauke J, Kluin RJC, Nederlof P, Richters LK, Krebsbach G, Sikorska K, Alkemade M, Opdam M, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, de Hingh IHJT, Mom CH, Arts HJG, van Ham M, van Dam P, Vuylsteke P, Sanders J, Horlings HM, van de Vijver KK, Hahnen E, van Driel WJ, Schmutzler R, Sonke GS, Linn SC. Koole SN, et al. Among authors: arts hjg. Int J Cancer. 2022 Oct 15;151(8):1394-1404. doi: 10.1002/ijc.34124. Epub 2022 Jun 4. Int J Cancer. 2022. PMID: 35583992 Free article. Clinical Trial.
Time to stop ovarian cancer screening in BRCA1/2 mutation carriers?
van der Velde NM, Mourits MJ, Arts HJ, de Vries J, Leegte BK, Dijkhuis G, Oosterwijk JC, de Bock GH. van der Velde NM, et al. Int J Cancer. 2009 Feb 15;124(4):919-23. doi: 10.1002/ijc.24038. Int J Cancer. 2009. PMID: 19035463 Free article.
The prognostic value of TRAIL and its death receptors in cervical cancer.
Maduro JH, Noordhuis MG, ten Hoor KA, Pras E, Arts HJ, Eijsink JJ, Hollema H, Mom CH, de Jong S, de Vries EG, de Bock GH, van der Zee AG. Maduro JH, et al. Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):203-11. doi: 10.1016/j.ijrobp.2009.03.071. Int J Radiat Oncol Biol Phys. 2009. PMID: 19695437
Laparoscopy to predict the result of primary cytoreductive surgery in advanced ovarian cancer patients (LapOvCa-trial): a multicentre randomized controlled study.
Rutten MJ, Gaarenstroom KN, Van Gorp T, van Meurs HS, Arts HJ, Bossuyt PM, Ter Brugge HG, Hermans RH, Opmeer BC, Pijnenborg JM, Schreuder HW, Schutter EM, Spijkerboer AM, Wensveen CW, Zusterzeel P, Mol BW, Kenter GG, Buist MR. Rutten MJ, et al. BMC Cancer. 2012 Jan 20;12:31. doi: 10.1186/1471-2407-12-31. BMC Cancer. 2012. PMID: 22264278 Free PMC article. Clinical Trial.
Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study.
van de Laar R, Zusterzeel PL, Van Gorp T, Buist MR, van Driel WJ, Gaarenstroom KN, Arts HJ, van Huisseling JC, Hermans RH, Pijnenborg JM, Schutter EM, Pelikan HM, Vollebergh JH, Engelen MJ, Inthout J, Kruitwagen RF, Massuger LF. van de Laar R, et al. BMC Cancer. 2014 Jan 14;14:22. doi: 10.1186/1471-2407-14-22. BMC Cancer. 2014. PMID: 24422892 Free PMC article. Clinical Trial.
Laparoscopy to Predict the Result of Primary Cytoreductive Surgery in Patients With Advanced Ovarian Cancer: A Randomized Controlled Trial.
Rutten MJ, van Meurs HS, van de Vrie R, Gaarenstroom KN, Naaktgeboren CA, van Gorp T, Ter Brugge HG, Hofhuis W, Schreuder HW, Arts HJ, Zusterzeel PL, Pijnenborg JM, van Haaften M, Fons G, Engelen MJ, Boss EA, Vos MC, Gerestein KG, Schutter EM, Opmeer BC, Spijkerboer AM, Bossuyt PM, Mol BW, Kenter GG, Buist MR. Rutten MJ, et al. J Clin Oncol. 2017 Feb 20;35(6):613-621. doi: 10.1200/JCO.2016.69.2962. Epub 2016 Dec 28. J Clin Oncol. 2017. PMID: 28029317 Clinical Trial.
Cost-effectiveness of laparoscopy as diagnostic tool before primary cytoreductive surgery in ovarian cancer.
van de Vrie R, van Meurs HS, Rutten MJ, Naaktgeboren CA, Opmeer BC, Gaarenstroom KN, van Gorp T, Ter Brugge HG, Hofhuis W, Schreuder HWR, Arts HJG, Zusterzeel PLM, Pijnenborg JMA, van Haaften M, Engelen MJA, Boss EA, Vos MC, Gerestein KG, Schutter EMJ, Kenter GG, Bossuyt PMM, Mol BW, Buist MR. van de Vrie R, et al. Among authors: arts hjg. Gynecol Oncol. 2017 Sep;146(3):449-456. doi: 10.1016/j.ygyno.2017.06.019. Epub 2017 Jun 20. Gynecol Oncol. 2017. PMID: 28645428 Clinical Trial.
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.
van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, de Hingh IHJT, van der Velden J, Arts HJ, Massuger LFAG, Aalbers AGJ, Verwaal VJ, Kieffer JM, Van de Vijver KK, van Tinteren H, Aaronson NK, Sonke GS. van Driel WJ, et al. N Engl J Med. 2018 Jan 18;378(3):230-240. doi: 10.1056/NEJMoa1708618. N Engl J Med. 2018. PMID: 29342393 Free article. Clinical Trial.
Health-related quality of life after interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage III ovarian cancer.
Koole SN, Kieffer JM, K Sikorska, Schagen van Leeuwen JH, Schreuder HWR, Hermans RH, de Hingh IH, van der Velden J, Arts HJ, van Ham MAPC, Aalbers AG, Verwaal VJ, Van de Vijver KK, Sonke GS, van Driel WJ, Aaronson NK. Koole SN, et al. Eur J Surg Oncol. 2021 Jan;47(1):101-107. doi: 10.1016/j.ejso.2019.05.006. Epub 2019 May 13. Eur J Surg Oncol. 2021. PMID: 31128948 Clinical Trial.
54 results